Tech Transfer eNews Blog

University start-up acquired in one of largest biotech deals in Australia and Ireland


By Jesse Schwartz
Published: September 23rd, 2020

A start-up based on a research collaboration between the University of Queensland (UQ) and Trinity College Dublin (TCD) has been acquired in one of the largest deals in Australian and Irish biotech history.

Founded in 2016, Inflazome develops treatments for inflammatory diseases by targeting inflammasomes, which are understood to drive many such diseases. Roche, a Swiss multinational healthcare company, has acquired Inflazome for an upfront cash payment of €380 million (about $445 million US), in addition to payments based on the achievements of certain milestones.

Under the terms of the acquisition, Roche will have full rights to the start-up’s portfolio of inflammasome inhibitors.

“This is wonderful news, first and foremost, for the many people across the world with diseases like Parkinson’s who stand to benefit from these discoveries. It is also a boost for the Irish scientific community and for Trinity College Dublin, where the ideas originated that led to the collaboration with UQ and the subsequent foundation of Inflazome,” says Patrick Prendergast, provost of TCD.

“Investigator-led research drives the innovation economy,” he adds, “and this news offers tangible evidence of its importance and also what can be achieved through partnership.”

“This is an outstanding outcome for the company, both universities, the researchers and the investors,” says Deborah Terry, vice chancellor and president of UQ. “Now more than ever, the value of research translation to support the recovery of our economies cannot be understated.

This deal reinforces the importance of research collaboration and shows what can be achieved through commercialization.”

Source: UQ News

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment